< Back to previous page
Researcher
Wim Robberecht
- Disciplines:Neurosciences, Biological and physiological psychology, Cognitive science and intelligent systems, Developmental psychology and ageing
Affiliations
- Laboratory for Neurobiology (VIB-KU Leuven) (Lab)
Member
From1 Jan 2012 → Today - Research Group Experimental Neurology (Division)
Member
From1 Oct 1999 → 31 Dec 2011
Projects
21 - 29 of 29
- Identifying modifying factors in stroke etiology and recoveryFrom1 Oct 2010 → 30 Sep 2012Funding: BOF - Other initiatives
- Axonal determinants as modifiers of motor neuron degeneration - A translational approach.From1 Oct 2010 → 30 Sep 2015Funding: BOF - Concerted Research Project from 1994
- Translational research into the role of the ephrin receptor EphA4 in the mechanism of motor neuron degeneration in amyotrophic lateral sclerosis.From1 Jan 2010 → 31 Dec 2015Funding: FWO research project (including WEAVE projects)
- Ephrins in neurodegeneration.From1 Oct 2009 → 21 Jan 2016Funding: IWT personal funding - strategic basic research grants
- The role and therapeutical potential of oxygen sensors in amyotrophic lateral sclerosis.From1 Oct 2009 → 3 Oct 2014Funding: FWO fellowships
- The role of progranulin in neurodegeneration.From1 Sep 2009 → 13 May 2014Funding: IWT personal funding - strategic basic research grants
- Acetylationat the active zones and implications of ALSFrom1 Aug 2009 → 19 Nov 2013Funding: Own budget, for example: patrimony, inscription fees, gifts
- Mechanisms in Amyotrophic Lateral Sclerosis: from genetic linkage to novel insightsFrom1 Oct 2008 → 15 May 2013Funding: Own budget, for example: patrimony, inscription fees, gifts
- Microtubules in the pathogenesis of neurodegenerative diseases.From1 Jan 2008 → 21 Jun 2012Funding: IWT personal funding - strategic basic research grants
Publications
1 - 10 of 198
- The contribution of Neanderthal introgression and natural selection to neurodegenerative diseases(2023)
Authors: Wim Robberecht
- Telomere length analysis in amyotrophic lateral sclerosis using large-scale whole genome sequence data(2022)
Authors: Wim Robberecht, Philip Van Damme
- The SOD1-mediated ALS phenotype shows a decoupling between age of symptom onset and disease duration(2022)
Authors: Wim Robberecht, Philip Van Damme
- Structural variation analysis of 6,500 whole genome sequences in amyotrophic lateral sclerosis(2022)
Authors: Wim Robberecht, Philip Van Damme
- The Effect of SMN Gene Dosage on ALS Risk and Disease Severity(2021)
Authors: Wim Robberecht, Philip Van Damme
Pages: 686 - 697 - AAV9-mediated gene delivery of MCT1 to oligodendrocytes does not provide a therapeutic benefit in a mouse model of ALS(2021)
Authors: Elisabeth Rossaert, Sebastian Munck, Philip Van Damme, Matthew Holt, Ludo Van Den Bosch, Wim Robberecht
Pages: 508 - 519 - STING-Induced Inflammation - A Novel Therapeutic Target in ALS?(2021)
Authors: Philip Van Damme, Wim Robberecht
Pages: 765 - 767 - SCFD1 expression quantitative trait loci in amyotrophic lateral sclerosis are differentially expressed(2021)
Authors: Philip Van Damme, Wim Robberecht
- Exploration of the role of EphA4 in neurodegenerative diseases.(2020)
Authors: Lindsay Poppe, Wim Robberecht, Philip Van Damme
- Environmental enrichment during the chronic phase after experimental stroke promotes functional recovery without synergistic effects of EphA4 targeted therapy(2020)
Authors: Lindsay Poppe, Wim Robberecht, Robin Lemmens
Pages: 605 - 617
Patents
1 - 6 of 6
- Single domain antibodies against sod1 and their use in medicine (Inventor)
- Hdac inhibitors to treat charcot-marie-tooth disease (Inventor)
- SINGLE DOMAIN ANTIBODIES AGAINST SOD1 AND THEIR USE IN MEDICINE (Inventor)
- HDAC inhibitors to treat charcot-marie-tooth disease (Inventor)
- SINGLE DOMAIN ANTIBODIES AGAINST SOD1 AND THEIR USE IN MEDICINE (Inventor)
- USE OF EPHRIN TYPE-A RECEPTOR 4 SIGNALING INHIBITOR FOR TREATMENT OF MOTOR NEURON DISEASE CHOSEN FROM AMYOTROPHIC LATERAL SCLEROSIS AND SPINAL MUSCULAR ATROPHY (Inventor)